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Key points summary 
 
• Orexins are well described for their excitatory actions on feeding- and arousal-
promoting brain centres. 
• We describe here an inhibitory action of orexin-A on synaptic NMDA receptors 
in hippocampus, a key area for synaptic plasticity and memory formation. 
• Orexin-A inhibited NMDA receptor responses at mossy fibre-CA3 connections 
through postsynaptically expressed orexin-2 receptors, whereas a minor 
inhibition was observed at Schaffer collateral-CA1 connections, and no effect 
occurred at non-mossy fibre excitatory synapses in CA3. 
• Exogenously applied orexin-A inhibited NMDA receptors in slices prepared 
during the rats’ resting phase, when endogenous orexin levels are low, but not 
in slices prepared in the active phase, when endogenous orexins peak. 
• Through intraperitoneal administration of an orexin receptor antagonist during 
the active period, exogenous orexin-A-mediated inhibition was restored in the 
slice. 
• Endogenous orexins suppress hippocampal synaptic NMDA receptor function 
in a diurnally cyclic manner, likely restraining synaptic plasticity and learning 
during certain periods of waking. 
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Abstract 
Diurnal release of the orexin neuropeptides, orexin-A (ox-A, hypocretin-1) and orexin-
B (ox-B, hypocretin-2), stabilises arousal, regulates energy homeostasis and 
contributes to cognition and learning. However, whether cellular correlates of brain 
plasticity are regulated through orexins, and whether they do so in a time-of-day-
dependent manner, has never been assessed. Immunohistochemically, we found 
sparse but widespread innervation of hippocampal subfields through ox-A- and ox-B-
containing fibres in young adult rats. The actions of ox-A were studied on NMDA 
receptor (NMDAR)-mediated excitatory synaptic transmission in acute hippocampal 
slices prepared around the trough (Zeitgeber Time (ZT) 4-8, corresponding to 4-8 h 
into the resting phase) and peak (ZT 23) of intracerebroventricular orexin levels. At 
ZT 4-8, exogenous ox-A (100 nM in bath) inhibited NMDA-EPSCs at mossy fibre 
(MF)-CA3 (to 55.6 ± 6.8% of control, P = 0.0003) and at Schaffer collateral-CA1 
synapses (70.8 ± 6.3%, P = 0.013), whereas it remained ineffective at non-MF 
excitatory synapses in CA3. Ox-A actions were mediated postsynaptically and 
blocked by the orexin-2 receptor (OX2R) antagonist JNJ10397049 (1 μM), but not by 
OX1R inhibition (SB334867, 1 μM) or by adrenergic and cholinergic antagonists. At 
ZT 23, inhibitory effects of exogenous ox-A were absent (97.6 ± 2.9%, P = 0.42), but 
reinstated (87.2 ± 3.3%, P = 0.002) when endogenous orexin signalling was 
attenuated for 5 hours through I.P. injections of almorexant (100 mgkg-1), a dual 
orexin receptor antagonist. In conclusion, endogenous orexins modulate 
hippocampal NMDAR function in a time-of-day-dependent manner, suggesting that 
they may influence cellular plasticity and consequent variations in memory 
performance across the sleep-wake cycle. 
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Abbreviation list 
A/C, associational/commissural; Alm, almorexant; DAB, 3,3′-diaminobenzidine ; DG, 
dentate gyrus; LD, light/dark; LFF, low-frequency facilitation; LTP, long-term 
potentiation; MF, mossy fibre; mGluR, metabotrobic glutamate receptor; NMDAR, 
NMDA receptor; PKC, protein kinase-C; ox-A, orexin-A; ox-B, orexin-B; OX1R, 
orexin-1 receptor; OX2R, orexin-2 receptor; Ri, input resistance; Rs, series 
resistance; RT, room temperature; s., stratum; SC, Schaffer collaterals; TBS, Tris-
buffered solution; Veh, vehicle; ZT, Zeitgeber Time. 
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Introduction  
From rodent to human, a few thousand to ten-thousand neurones in the lateral 
hypothalamus form a brain-wide axonal projection system that regulates many 
physiological and behavioural processes via releasing two orexin peptides, orexin-A 
(ox-A, hypocretin-1) and orexin–B (ox-B, hypocretin-2). The densest projections 
formed by these orexinergic neurones are found in wake-promoting and feeding 
control centres (Peyron et al., 1998), in the mesolimbic dopaminergic reward system 
(Fadel & Deutch, 2002), and in the spinal cord autonomic tracts (van den Pol, 1999). 
Today, a complex picture of orexinergic function is emerging, in which energy 
homeostasis and arousal stability are coordinated with adaptation of the organism to 
environmental challenge (Li et al., 2013). In line with orexin neurones promoting 
waking and energy expenditure, orexinergic concentration in the cerebral spinal fluid 
(Zhang et al. 2004) and in the lateral hypothalamic area (Yoshida et al., 2001) is high 
(hundreds of nanomolar) during the active state, whereas it declines during the 
resting phase. Via the G-protein-coupled orexin-1 receptors (OX1Rs) and orexin-2 
receptors (OX2Rs), orexin peptides are known for their excitatory effects induced 
through postsynaptic depolarisation or facilitation of repetitive action potential 
discharge at subcortical and cortical levels of the wake-promoting system (Horvath et 
al., 1999; Brown et al., 2001; Eriksson et al., 2001; Bayer et al., 2002; Burlet et al., 
2002; Zhang et al., 2010), presynaptic facilitation of neurotransmitter release (van 
den Pol et al., 1998; Burlet et al., 2002; Li et al., 2002; Lambe & Aghajanian, 2003), 
or through promoting membrane insertion of NMDA receptor (NMDAR) subunits at 
synapses (Borgland et al., 2006). 
More recent studies implicate orexins in cognitive processes, involving attention 
and memory formation (Jaeger et al., 2002; Lambe et al., 2005; Deadwyler et al., 
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2007; Boschen et al., 2009; Sears et al., 2013). Activation of arousal systems, such 
as the locus coeruleus and the basal forebrain (Boschen et al., 2009; Sears et al., 
2013; Soya et al., 2013), and stimulation of thalamocortical circuits (Lambe et al., 
2005; Deadwyler et al., 2007; Mair & Hembrook, 2008) are some of the brain 
mechanisms by which orexins promote cognitive performance. In contrast, few and 
partially contradictory pieces of evidence support a hippocampal involvement in 
orexinergic actions on cognitive function. Hippocampus-dependent spatial memory, 
as assessed with rats in the Morris Water Maze task, reportedly is compromised by 
hippocampal or intracerebroventricular infusion of either agonists or antagonists of 
orexin receptors (Aou et al., 2003; Akbari et al., 2006, 2007). Ox-A also attenuates 
NMDAR-dependent long-term potentiation (LTP) and NMDAR-mediated field 
potentials at Schaffer collateral (SC)-CA1 synapses in vitro (Aou et al., 2003; Selbach 
et al., 2004; Doreulee et al., 2009), whereas it indirectly upregulates glutamatergic 
synaptic strength at different hippocampal synapses (Selbach et al., 2004; Walling et 
al., 2004) and boosts LTP in dentate gyrus (DG) in vivo (Wayner et al., 2004). 
Immunohistochemistry consistently reveals the presence of orexinergic fibres 
throughout hippocampal areas, but fibre density is low (Peyron et al., 1998; Selbach 
et al., 2004; Morales et al., 2006). OX1Rs and OX2Rs are expressed in all 
hippocampal areas at the mRNA and protein levels (Hervieu et al., 2001; Marcus et 
al., 2001; Cluderay et al., 2002; Ito et al., 2008). Taken together, these studies 
suggest that orexin neurones innervate the hippocampal formation to, directly and/or 
indirectly, regulate synaptic function. However, whether endogenous orexins indeed 
act on hippocampal circuits and what their primary synaptic targets are has not been 
investigated. 
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Using ex vivo slice recordings and pharmacological interference with orexin 
signalling in the rat, this study defines the role of orexins at hippocampal excitatory 
synapses by focusing on the following questions. Do orexins directly control 
hippocampal excitatory synaptic transmission? If yes, what is the role played by 
synaptic NMDARs? Do endogenous orexins act on these targets in a manner 
consistent with their time-of-day-dependent release?  
We found that exogenously applied ox-A inhibited NMDAR function at two major 
hippocampal synapses, with a stronger effect at mossy fibre (MF)-CA3 compared to 
SC-CA1 synapses. Our data also indicate that MF-NMDAR function is suppressed by 
orexins released during periods of waking, while they recover during rest, suggesting 
a diurnal regulation of NMDAR properties at a key synapse of the hippocampal 
trisynaptic circuit. 
 
Methods  
Animals 
Pregnant (E14) Sprague Dawley dams were obtained from Janvier Labs, 
France, and kept in a 12 h/12 h light/dark (LD) cycle (lights on at 7 a.m.), with food 
and water provided ad libitum, in a room controlled for temperature and humidity 
(~24°C, 30-40%) in standard Makrolon cages (22 cm x 39 cm). For some 
experiments, mothers with their pups (P7) were shifted to a LD cycle from 2 p.m. - 2 
a.m. (lights on at 2 p.m.), through increasing time steps of 1-2 h per day. The rats 
were kept in these conditions for at least an additional week before use. Experiments 
were performed on P19-P30 offsprings. All experimental procedures conformed to 
the policies of the Veterinary Office of the Canton de Vaud. 
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Immunohistochemistry  
Several three-week-old rats were kept under deep anaesthesia using 4-5% 
isofluorane and were transcardially perfused with 5-10 ml of 0.9% NaCl followed by 
~500 ml of an ice-cold fixative solution (4% paraformaldehyde in 0.1 mM phosphate 
buffer, pH 7.4). The brains were extracted, post-fixed in the same fixative for 2 h at 
4°C and cryopreserved in increasing sucrose gradients (10-20-30% in PBS) at 4°C. 
Coronal sections (45 μm) were cut with a freezing microtome and collected in PBS. 
Free-floating sections were incubated with 2% methanol and 0.3% H2O2 in PBS for 
30 min at room temperature (RT) to quench the endogenous peroxidases. Sections 
were washed in PBS, kept for 45 min in a blocking solution containing 2% normal 
horse serum and 0.3% Triton X-100 in PBS, and then incubated overnight at 4°C with 
an ox-A or ox-B primary antibody (goat polyclonal antibodies raised against the C-
terminus of ox-A or ox-B of human origin; 1:1000 diluted in blocking solution, Santa 
Cruz Biotech.). After several rinses with PBS, sections were incubated with the biotin-
SP-conjugated secondary antibody (1:500 diluted in PBS, biotin-SP-conjugated 
AffiPure Donkey Anti-Goat IgG, Jackson ImmunoResearch) for 2 h at RT. 
Subsequently, sections were washed with a Tris-buffered saline (TBS, 0.1 M Tris and 
0.9% NaCl, pH 8) and incubated in the avidin-biotin-peroxidase complex (Vectastain 
Elite ABC-peroxidase kit, Vector Lab Inc.) diluted 1:100 in the same Tris-buffered 
solution. After being rinsed in a different TBS (0.05 M Tris and 0.9% NaCl, pH 7.6), 
sections were incubated with 3,3′-diaminobenzidine (DAB, 0.04%) and 0.015% H2O2 
diluted in TBS (0.05 M Tris and 0.9% NaCl, pH 7.6), to allow the DAB oxidation and 
precipitation. As negative control, the immunostaining procedure was performed in 
the absence of the primary antibodies and resulted in a lack of labelling. The sections 
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were mounted on glass slides (SuperFrostPlus, Menzer-Gläser), dehydrated in an 
ascending series of ethanol, cleared in xylol and coverslipped with Eukitt mounting 
medium (Reactolab). Illustrations for Fig. 1 were taken from the sections of one rat. 
 
Electrophysiological recordings   
Rats were deeply anaesthetised with 4-5% isofluorane and immediately 
decapitated. Hippocampal slices were prepared according to two previously 
described procedures, depending on the type of NMDAR-mediated response 
recorded. The standard time of slice preparation was at Zeitgeber Time (ZT) 4 
(corresponding to 4 h into the resting phase). For some experiments, slices were 
prepared at ZT 8 or ZT 23, as specified in the text. For most of the recordings of 
NMDA-EPSCs at MF-CA3 synapses (MF-NMDA-EPSCs), hippocampi were 
dissected and cut as described (Kwon & Castillo, 2008a) to optimally preserve the 
integrity of MF projections. For some of the initial recordings of MF-NMDA-EPSCs, 
for SC-CA1 NMDA-EPSCs and for iontophoretic NMDAR-mediated currents (NMDA-
currents), parasagittal slices from whole brains were prepared (Bischofberger et al., 
2006). For slice preparation from dissected hippocampi, the brain was quickly 
immersed in an ice-cold oxygenated (95%/5%, O2/CO2) sucrose solution containing 
(in mM): 213.3 sucrose, 2.5 KCl, 1.3 NaH2PO4, 26 NaHCO3, 7 MgCl2, 0.5 CaCl2, 25 
glucose, 1.7 L(+)-ascorbic acid. Entire hippocampi were gently removed and cut 
parasagittally while being fixed in an agar cube glued to the stage of the vibratome 
(HM650V, Microm). Slices (400 µm) were incubated in a recovery chamber filled with 
a solution made of sucrose solution and ACSF, mixed at 1:1, for 30 min at RT, which 
was subsequently replaced by standard ACSF. The ACSF contained (in mM): 117.7 
NaCl, 2.5 KCl, 1.3 NaH2PO4, 26 NaHCO3, 1.2 MgCl2, 2 CaCl2, 25 glucose, 1.7 L(+)-
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ascorbic acid. For parasagittal hippocampal slices cut from entire brain, the brain was 
quickly immersed in an ice-cold oxygenated solution containing (in mM): 58.8 NaCl, 
105 sucrose, 2.5 KCl, 1.3 NaH2PO4, 26 NaHCO3, 7 MgCl2, 0.5 CaCl2, 25 glucose, 1.7 
L(+)-ascorbic acid and 2 kynurenic acid. Slices (400 µm) were cut with the vibratome 
and incubated at 35°C for 30 min in a storage chamber filled with ACSF, followed by 
cooling to RT.  
For whole-cell voltage-clamp recordings, patch pipettes (3-3.5 MΩ) were 
pulled from borosilicate glass (TW150F-A, WPI) and filled with the following 
intracellular solution (in mM): 120 Cs-methanesulphonate, 10 CsCl, 10 HEPES, 8 
NaCl, 0.5 EGTA, 4 Mg-ATP, 10 phosphocreatine, adjusted to pH 7.3-7.4 with CsOH 
and to 300-305 mOsm. Na-GTP (0.2 mM) and N-(2,6-
dimethylphenylcarbamoylmethyl) TEA chloride (QX-314 chloride, 2 mM) were freshly 
added and the solution was filtered and kept on ice. 
Slices were perfused with oxygenated ACSF in the recording chamber at a 
rate of ~3-3.5 mlmin-1 and recordings were performed at RT. Pyramidal neurone 
layers were visualised using near-infrared differential interference contrast 
microscopy (BX51WI, Olympus), but cells were recorded “semi-blind” or “blind” at 
depths >100 µm below the surface to target cells with largely preserved neurites and 
maximal vitality. Voltage-clamp recordings were obtained using a Multiclamp 700B 
amplifier (Molecular Devices), filtered at 2 kHz and sampled at 10 kHz, using 
Clampex 10.2 (Molecular Devices). Series resistance (Rs) was monitored during the 
experiments and changes >15% were not accepted. A liquid junction potential of ~-7 
mV, measured as previously described (Neher, 1992), was not compensated for. 
NMDA-EPSCs were pharmacologically isolated through continuous bath application 
of oxygenated ACSF containing (in µM): 40 6,7-dinitroquinoxaline-2,3-dione (DNQX), 
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100 picrotoxin, 2(2S)-3-[[(1S)-1-(3,4-dichlorophenyl)ethyl]amino-2hydroxypropyl] 
(phenylmethyl) phosphinic acid hydrochloride (CGP55845) to block AMPA, GABAA 
and GABAB receptors, respectively, and recorded at +30 mV. The NMDAR co-
agonist glycine (1 µM) was also included in the bath. MF-AMPA-EPSCs were 
recorded at -60 mV in ACSF supplemented with (in µM): 100 picrotoxin, 2 
CGP55845, 100 D,L-2-amino-5-phosphonopentanoic acid (D,L-APV). In this case, TTX 
was included at 30 nM to avoid polysynaptic contamination (Kwon & Castillo, 2008b).  
Synaptic currents were elicited by brief current pulses (100 µs, 50-150 µA) 
through monopolar (saline-filled patch pipette) or bipolar tungsten electrodes (FHC 
Inc.). Mossy fibres were stimulated by placing the stimulation electrode in the granule 
cell layer of the DG, whereas associational/commissural (A/C) synapses and 
entorhinal inputs, referred to as non-MF synapses, were activated in the hilus/stratum 
(s.) lucidum of CA3, and SCs were recruited in s. radiatum of the CA1. To 
demonstrate the identity of MF-induced responses, the group II metabotropic 
glutamate receptor (mGluR2) agonist (2’S,2’R,3’R)-2-(2’,3’-
dicarboxycyclopropyl)glycine (DCG-IV), 1 µM, was always applied at the end of the 
experiments (Kamiya et al., 1996). When the EPSC amplitude was reduced by > 
80%, EPSCs were included as MF-mediated responses. When the reduction was ≤ 
60%, recordings were considered of predominant non-MF origin. SC-NMDA-EPSCs 
were routinely blocked by D,L-APV (100 µM) at the end of the experiments. Five 
experiments yielding intermediate DCG-IV sensitivity (60-80%) were included only in 
the linear regression analysis between DCG-IV and ox-A sensitivity (Fig. 2D). 
Iontophoretic NMDA-currents were elicited through a patch pipette filled with 
10 mM NMDA (in ACSF), placed either at the proximal apical dendrite (within 100 µm 
from the soma in s. lucidum) or at the distal apical dendrite (> ~250 µm from the 
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soma in s. radiatum) to preferentially activate MF or non-MF inputs, respectively. 
NMDA was ejected once per min by applying currents of 200-500 nA and 1 s 
duration. Cellular currents were recorded at +30 mV in ACSF containing (in µM): 1 
glycine, 40 DNQX, 100 picrotoxin, 2 CGP55845 and 0.5 TTX. Retention currents of 
10-20 nA were used in between ejections. The ejection area was visualised by 
fluorescence microscopy after including Alexa 594 (1 μM) in the pipette, which 
covered 94 ± 20 µm of proximal dendritic length (n = 3 measurements). 100 µM D,L-
APV was applied at the end of the recording to block the NMDA-currents.  
Ox-A was applied through the bath and dissolved at the desired solution 
immediately before application. Time points of ox-A application were between 114 
and 405 min after slice preparation for both MF stimulation and iontophoretic NMDA 
application. In none of these experimental series there was a significant correlation 
between the time of recording and the amplitude of the ox-A effect, as assessed by a 
least-squares linear fit (Pearson’s correlation coefficients R2 = 0.002 and 0.02 for MF 
stimulation (n = 10) and NMDA iontophoresis (ZT 4, n = 12), respectively, P > 0.05 
for both). 
 
Analysis of electrophysiological recordings 
Current amplitudes were measured in a 4 ms (EPSCs) or 200 ms 
(iontophoresis) time window around the peak of the event. Inhibitory effects of ox-A 
were calculated when steady-state was reached, typically 10 min after onset of bath 
application. DCG-IV effects were measured after 10 min and D,L-APV after 5 min of 
wash-in. Currents were normalised to the corresponding mean baseline amplitudes. 
The decay time of currents was calculated by dividing the charge transfer by the 
mean amplitude of the NMDA-EPSCs or NMDA-currents (Longordo et al., 2009). 
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Charge transfer was calculated between the peak time and the time of return to 
baseline (for EPSCs ~ 1 s after peak, for iontophoretic currents ~30 s after the peak). 
The IC50 and the Hill coefficient for ox-A-suppression of MF-NMDA-EPSCs were 
calculated by fitting the data with the Hill equation. Least-squares linear fits were 
performed in JMP 9.0.0. 
 
Behavioral monitoring and almorexant injections 
For these experiments, animals were shifted to a LD cycle of 2 p.m. – 2 a.m. 
At P20-21, each rat was transferred singly into a larger cage (53 cm x 31.5 cm) with 
34 cm-high transparent walls and with a dark bedding made of various tree barks 
(Zoosano AG, Switzerland) or Cellu-Dri Soft bedding (Shepherd Specialty Papers). 
As enrichment, pieces of black cardboard were put in the cage. Animals were 
monitored for their sleep-wake behaviour over 48 h (24 h baseline trial (Bsl), 24 h 
injection trial (Inj) through tracking the spontaneous locomotor activity (distance 
travelled per unit of recording time), using an infrared-sensitive camera (Ikegami 
ICD47E) and Ethovision XT8 software (Noldus Information Technology). The dual 
orexin receptor antagonist (2R)-2-{(1S)-6,7-dimethoxy-1-[2-(4-trifluoromethylphenyl)-
ethyl]-3,4-dihydro-1H-isoquinolin-2-yl}-N-methyl-2-phenyl-acetamide (almorexant, 
Alm) was suspended in 200 µl of 0.25% methyl cellulose (Sigma-Aldrich) immediately 
before injections and injected I.P. at 100 mgkg-1 under red light illumination. In a 
preliminary trial test, we observed that the action of Alm (100 mgkg-1) on the rats’ 
resting time lasted for up to ~ 3 h after the injection. We administered two injections 
at ZT 18 and 21 of the Inj trial to maintain the resting state for the entire second half 
of the dark, active phase. In parallel to the rat group injected with Alm (Alm group), 
the control group (Veh group) was injected at the same ZTs with equal volumes of 
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0.25% methyl cellulose, the vehicle (Veh). After the two injections, rats were removed 
from the cage at ZT 23 and anaesthetised within 30 s for slice preparation. 
 
Analysis of behavioural data  
The resting time was calculated as hourly % of time during which the rat’s 
centre of gravity moved at < 1 cms-1. This threshold was set during a visually 
identified resting episode. For the 24 h Bsl trial, mean resting times were calculated 
for the 12 h light and 12 h dark periods. For the 24 h Inj trial, means of 5 h resting 
time (ZT 18 – 23) during the injections were taken for comparison between animals 
injected with Alm or Veh. 
 
Drugs and chemicals  
Picrotoxin, D,L-APV, DNQX, CGP55845 hydrochloride and kynurenic acid were 
purchased from Abcam; TTX from Latoxan; NMDA, glycine, D,L-propranolol and 
methyl cellulose from Sigma-Aldrich; ox-A, DCG-IV, N-(2-Methyl-6-benzoxazolyl)-N'-
1,5-naphthyridin-4-yl urea (SB334857), scopolamine hydrobromide, prazosin 
hydrochloride from Tocris-R&D systems; 1-(2,4-dibromophenyl)-3-[(4S,5S)-2,2-
dimethyl-4-phenyl-1,3-dioxan-5-yl] urea (JNJ10397049) was a generous gift from Dr. 
Mauro Corsi and Dr. Corrado Corti (Aptuit, Verona, Italy). Alm was kindly provided by 
Prof. Mehdi Tafti and Dr. Anne Vassalli (CIG-UNIL). 
 
Statistics 
15 
 
All data are given as means ± SEM. Statistics were done using Student’s t-tests as 
follows: Electrophysiological data were assessed with two-tailed paired Student’s t-
tests comparing raw datasets for baseline and test conditions in Excel. Two-tailed 
paired Student’s t-tests were also used to compare resting times of rats across the 
light-dark cycle and between the Bsl and the Inj Trials. Unpaired Student’s t-tests 
were used for comparison between conditions using normalised data both in 
electrophysiological and behavioural analyses. Correlation coefficients of linear 
regressions were obtained in JMP 9.0.0. The level of significance was set at P < 
0.05. 
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Results 
Orexin-A suppresses NMDA-EPSCs at MF synapses through a postsynaptic 
mechanism 
We first tested whether 3-week-old Sprague Dawley rats expressed 
immunoreactivity for orexins in hippocampus. With antibodies recognising the C-
terminus of ox-A and ox-B, previously used for hippocampal immunostaining of 
orexins (Morales et al., 2006), we identified heavily stained cell bodies and fibres in 
the lateral hypothalamic area (not shown), consistent with the described location of 
orexin neurones (Peyron et al., 1998). Individual immunoreactive fibres were clearly 
present within the CA3 and CA1 areas, as well as in the DG (Fig. 1Aa, Ab). Ox-A or 
ox-B-expressing fibres, ranging from ~20 to ~270 μm in length within the 45 μm-thick 
coronal section, were sparse and located throughout all layers, crossing s. 
pyramidale in CA3 and CA1 to enter s. lucidum and s. radiatum, respectively. In the 
DG, ox-A and ox-B-positive short fibres appeared mostly in close proximity to the 
granule cell layer.  
To evaluate the physiological effects of orexin on hippocampal NMDARs, we 
prepared acute hippocampal slices at ZT 4 (see Methods), corresponding to 11 a.m. 
in the light phase (lights on at 7 a.m.). Pharmacologically isolated NMDA-EPSCs 
were evoked at 0.033 Hz in CA3 or CA1 pyramidal neurones held at +30 mV. 
Stimulation was achieved via monopolar or bipolar extracellular electrodes positioned 
in the DG for MF stimulation and in s. radiatum for stimulation of SCs (see Methods 
and insets in Fig. 1B and E). Mean baseline NMDA-EPSCs had an amplitude of 57 ± 
5 pA (n = 10) in CA3 neurones, and 87 ± 8 pA in CA1 neurones (n = 4). Orexinergic 
actions were examined through bath application of ox-A, which shows comparable 
affinity for both orexin receptor types (Sakurai et al., 1998). At 100 nM, ox-A 
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decreased the amplitude of NMDA-EPSCs to 55.6 ± 6.8% (38 ± 4 pA, n = 10, P = 
0.0003) of baseline at MF-CA3 (Fig. 1B), and to 70.8 ± 6.3% (61 ± 9 pA, n = 4, P = 
0.013) at SC-CA1 synapses (Fig. 1E). The effect reached a maximum after 7-10 min 
of application and recovered partially in the case of MF-NMDA-EPSCs upon wash-
out of ox-A. Holding current remained unaltered after ox-A application in these cells 
(651± 50 pA vs. 653 ± 59 pA in ox-A, P = 0.9 for MF-CA3 recordings, 344 ± 52 pA vs. 
341 ± 52 pA, P = 0.5 for SC-CA1 recordings). The input resistance (Ri) weakly 
increased 10 min after ox-A application (for CA3 pyramidal neurones: 53 ± 4 MΩ vs. 
59 ± 5 MΩ in ox-A, P = 0.009, Fig. 1C; for CA1 pyramidal neurones: 89 ± 12 MΩ vs. 
95 ± 14 MΩ, P = 0.059, Fig. 1F). Continuous monitoring of cellular Rs indicated no 
changes during the recordings (< 10% change in DCG-IV vs. baseline, Fig. 1C and 
~10% change in D,L-APV vs. baseline, Fig. 1F). Ox-A slowed the decay time course 
of the synaptically elicited MF-NMDA-EPSCs in 9/10 cells (145 ± 14 ms vs. 211 ± 24 
ms after ox-A application, P = 0.0008) but not of SC-NMDA-EPSCs (208 ± 8 ms vs. 
237 ± 17 ms, P = 0.2, see Methods). The mGluR2 agonist DCG-IV (1 µM) largely 
abolished NMDA-EPSCs at MFs (7.6 ± 1.4 pA, n = 10, P < 0.0001, see Methods, Fig. 
1B). The NMDA-EPSCs recorded at SC-CA1 synapses were fully blocked by the 
NMDAR antagonist D,L-APV (100 µM, n = 4, Fig. 1E). 
The inhibitory effect of ox-A on NMDA-EPSCs at MF-CA3 synapses was 
concentration-dependent (Fig. 1D): NMDA-EPSCs were not affected by 1 nM ox-A, 
but reduced to a minimum of 33.5 ± 2.3% of baseline amplitude by 200 nM ox-A (n = 
2-10 per concentration tested). This concentration range corresponds to the one 
found in the cerebral spinal fluid (Yoshida et al., 2001) and overlaps with several 
concentration-functional response relations of heterologously expressed mouse 
OX2Rs (Chen & Randeva, 2004; Wang et al., 2014). Fitting of a sigmoidal Hill 
18 
 
function yielded an IC50 of 62 ± 17 nM and a Hill coefficient of 0.6 ± 0.1 (Fig. 1D). In 
all subsequent experiments, ox-A was applied at 100 nM to induce a close-to-
maximal suppression.  
In contrast to NMDA-EPSCs, no suppressant actions of ox-A were found at 
MF-AMPA-EPSCs. Amplitudes remained unaltered after 10 min in the continuous 
presence of ox-A (99.3 ± 9.5% of control, n = 3, P = 0.78), while they were fully 
blocked by DCG-IV (1 µM, Fig. 1G). 
To assess the synaptic specificity of ox-A actions, we recorded NMDA-EPSCs 
formed by A/C and entorhinal connections, referred to as non-MF connections. 
Stimulation of the s. lucidum/hilar regions elicited NMDA-EPSCs showing an 
intermediate to weak sensitivity to DCG-IV (40-60% reduction), indicating that a 
mixture of fibres of both MF and non-MF origin was recruited. The EPSCs were not 
affected by bath application of ox-A (89.5 ± 7.1%, n = 4, P = 0.31, Fig. 2A) and no 
significant changes occurred in holding currents after ox-A application (656 ± 64 pA 
vs. 558 ± 63 pA in ox-A, P = 0.2). Values for Ri were 44 ± 6 MΩ vs. 57 ± 5 MΩ in ox-
A (P = 0.053). We further assessed ox-A-mediated modulation of NMDARs on distal 
sites of CA3 cells by placing an iontophoresis pipette filled with NMDA (10 mM) at the 
distal apical dendrite of CA3 pyramidal neurones (s. radiatum, ~250 µm from the 
soma, see inset in Fig. 2B). Local pressure application of NMDA on CA3 cells has 
been previously used to study G-protein-mediated regulation of NMDARs (Benquet et 
al., 2002). NMDA-currents had a mean amplitude of 85 ± 12 pA and a mean decay 
time of 10.2 ± 1.0 s (n = 8, Fig. 2B), comparable to previous observations (Benquet et 
al., 2002). Ox-A (100 nM) applied in the bath neither affected amplitude (98.7 ± 3.6%, 
84 ± 12 pA, n = 8, P = 0.73) nor decay time (9.6 ± 1.0 s, P = 0.12) of these currents 
that were fully blocked by D,L-APV (100 µM) at the end of the experiments (Fig. 2B). 
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In contrast, NMDA-currents elicited iontophoretically on the proximal apical dendrite 
(within 100 µm from the soma, see inset in Fig. 2C), the site of MF synapses 
(Claiborne et al., 1986), were reduced by ox-A to 77.8 ± 3.9% (n = 9, P = 0.016, Fig. 
2C). Baseline NMDA-currents had a mean amplitude of 95 ± 13 pA and a mean 
decay time of 8.2 ± 1.6 s, whereas, in the presence of ox-A, amplitudes were 78 ± 11 
pA and decay time 7.5 ± 1.4 s. No recovery was observed up to 20 min after wash-
out. Currents were fully blocked by D,L-APV (100 µM) at the end of the experiment 
(Fig. 2C). In these experiments, the ox-A effects were smaller, probably because 
NMDARs at both MF- and non-MF synapses were recruited. Nevertheless, NMDA-
current measurements offered a rapid and reliable assay for further characterisation 
of ox-A actions on postsynaptic NMDARs. 
Taken together, we identified a specific inhibitory effect of ox-A on NMDA-
EPSCs at two sets of hippocampal synapses, with a major suppression at MF-CA3 
and a moderate effect at SC-CA1 synapses. Moreover, within the CA3 area, ox-A 
effects were confined to MF-CA3 synapses. This conclusion was further supported by 
the fact that the ox-A sensitivity of NMDA-EPSCs depended linearly on the DCG-IV 
sensitivity, which is an indicator of the relative presence of MFs in the stimulated fibre 
bundle (n = 14, Correlation coefficient 0.36, P = 0.022; Fig. 2D). For the further 
analysis of ox-A actions, the remainder of the study was focused on the MF-CA3 
pathway. 
Based on the clear ox-A effects on iontophoretic NMDA-currents, and on the 
lack of such on AMPA-EPSCs, it is likely that ox-A acted primarily post- rather than 
presynaptically. To further corroborate this, we examined whether ox-A affected low-
frequency facilitation (LFF), a well-characterised presynaptic form of short-term 
plasticity at MFs that sensitively reports on presynaptic receptor-induced changes in 
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release characteristics (for review, see (Evstratova & Tóth, 2014)). Baseline NMDA-
EPSCs elicited at 0.033 Hz were followed by a train of 20 pulses at 1 Hz during which 
NMDA-EPSC amplitude increased by 2- to 3-fold (297 ± 77% of baseline, n = 5, Fig. 
3A, B). Subsequent application of ox-A (100 nM) decreased the amplitude of the 
NMDA-EPSCs, but LFF developed to a comparable extent during 1 Hz stimulation 
(328 ± 97%, n = 5, P = 0.69 compared to baseline, Fig. 3A-C), thus excluding a 
primarily presynaptic mechanism for ox-A-inhibition of NMDAR-mediated synaptic 
responses.  
 
Orexin-A suppresses NMDA-currents through OX2Rs 
In situ hybridisation studies suggest that the OX2R is predominantly expressed 
in the CA3 area (Marcus et al., 2001). We examined the actions of potent and 
selective orexin receptor antagonists to test the functional involvement of OX1Rs and 
OX2Rs in ox-A actions on NMDA-currents. SB334867 selectively blocks OX1Rs in 
acute brain slices (Borgland et al., 2006; Li et al., 2010), whereas JNJ10397049 
abrogates OX2R actions in vitro (Borgland et al., 2008; Gozzi et al., 2011). When 
used at these previously established concentrations in the bathing solution, ox-A-
mediated actions on NMDA-currents elicited on proximal dendrites persisted in 
SB334867 (1 µM) (82.6 ± 1.7%, n = 7, P = 0.00003, Fig. 4A, Da), whereas they were 
entirely blocked by JNJ10397049 (1 µM) (97.3 ± 3.7%, n = 8, P = 0.34, Fig. 4B, Db). 
The extent of current reduction in SB334867 was comparable to that obtained when 
ox-A was applied alone (P = 0.49), whereas it was different in JNJ10397049 (P = 
0.003). In addition, ox-A actions were largely maintained when applied in the 
continuous presence of a cocktail of cholinergic (scopolamine hydrobromide, 10 μM) 
and adrenergic receptor antagonists (prazosin hydrochloride, 1 μM and D,L-
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propranolol, 1 μM) shown previously to interfere with ox-A actions on hippocampal 
excitatory transmission (Selbach et al., 2004; Doreulee et al., 2009) (81.4 ± 2.7%, n = 
5, P = 0.69 compared to control, Fig.4C, Dc). Therefore, ox-A acts primarily through 
postsynaptic OX2Rs to directly suppress NMDAR-mediated transmission at MF 
synapses.  
 
Ox-A-mediated suppression of NMDA-currents varies with time of day 
Is NMDAR function modified by endogenous orexins released within the 
hippocampus? The recent history of the animal’s sleep-wake behaviour prior to 
sacrifice can be traced in several synaptic characteristics of acute brain slices (Kopp 
et al., 2006; Kurotani et al., 2008; Lanté et al., 2011). Endogenous orexins fluctuate 
across the day, notably also in discrete brain areas innervated by orexinergic fibres 
(Yoshida et al., 2001; Zhang et al., 2004). Therefore, we examined whether 
exogenous ox-A effects on NMDA-EPSCs varied depending on the time of day of 
slice preparation.    
Slices were cut at ZT 23, corresponding to the last hour of the dark phase, 
during which ox-A reaches a peak, and compared to recordings from slices at ZT 4 or 
at ZT 8, at which ox-A concentrations are their lowest (Zhang et al., 2004), and at 
which the majority of our recordings were performed (Fig. 1-4). Application of 
exogenous ox-A (100 nM) did not affect NMDA-current amplitudes in brain slices 
prepared at ZT 23 (97.6 ± 2.9% baseline, n = 12, P = 0.42, Fig. 5A-C). On the 
contrary, in slices prepared in the period of low endogenous orexin levels (ZT 4 and 
ZT 8), bath application of ox-A invariably decreased the amplitude of NMDA-currents 
(77.2 ± 3.5% for ZT 4, n = 12, P = 0.006 and 80.4 ± 2.3% for ZT 8, n = 4, P = 0.022, 
Fig. 5A-C). Was the time-of-day dependence of ox-A actions due to elevated 
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amounts of endogenous orexins present in slices at ZT 23, but not at ZT 4 or ZT 8? 
High ambient neurotransmitter concentrations can be maintained in slices, as 
described for adenosine in the MF-CA3 synaptic environment (Moore et al., 2003). If 
endogenous orexin concentration remained high in our case, the actions of 
exogenous ox-A would be attenuated. However, the OX2R antagonist JNJ10397049 
(1 µM), when applied for a period of at least 25 min, did not affect NMDA-currents 
(100.3 ± 3.7% of amplitude before drug application, n = 6, P = 0.87, Fig. 5D), arguing 
against a tonic suppressive action of ambient orexins in the slice.  
Even without continued presence of the ligand, orexinergic modulation 
induced during waking could persist in the slice and attenuate or occlude the actions 
of exogenously added ox-A. Such modifications could have taken place at the level of 
the OX2Rs or the NMDARs, rendering further inhibitory effects of ox-A undetectable. 
In this case, NMDA-EPSCs recorded in slices prepared at ZT 23 should be smaller 
compared to those at ZT 4 or ZT 8. Such comparison, however, is experimentally 
difficult due to variable recruitment of MFs that, even in the dissected hippocampal 
preparation (Kwon & Castillo, 2008a), are left intact in the slice to only a very limited 
extent and at very restricted sites. To further define the role of endogenous orexins in 
the observed time-of-day dependence, we chose to pharmacologically interfere with 
orexinergic signalling prior to slice preparation. Almorexant (Alm) is a potent dual 
orexin receptor antagonist (Brisbare-Roch et al., 2007; Dugovic et al., 2009; Kang et 
al., 2009; Morairty et al., 2012) that crosses the blood-brain barrier (Brisbare-Roch et 
al., 2007) and that acts as a preferential OX2R antagonist in vivo (Dugovic et al., 
2009; Mang et al., 2012). This antagonist was injected I.P. into rats and video 
monitoring was used to follow the activity during the LD cycle in two groups of rats, 
one injected with Alm (Alm group, n = 8, 100 mgkg-1 I.P. in 0.25% methyl cellulose 
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suspension), the other one with vehicle (Veh) only (Veh group, n = 6, 0.25% methyl 
cellulose). For each group, a 24 h video monitoring of undisturbed baseline activity 
(Bsl Alm, Bsl Veh) was followed by a 24 h period when injections of Alm (Inj Alm) or 
Veh (Inj Veh) in the dark, active phase were applied. Activity monitoring during the 
Bsl trials indicated that both Alm and Veh groups were well entrained to the LD cycle, 
showing consistently higher resting time  during the light (ZT 1-12) than during the 
dark phase (ZT 13-24) (Bsl Alm: mean 12 h resting time, ZT 1-12: 63 ± 2.3%; ZT 13-
24: 45.1 ± 1.8%, n = 8, P = 0.018; Bsl Veh: mean 12 h resting time, ZT 1-12: 67 ± 
3.8%; ZT 13-24: 44.9 ± 3.4%, n = 6, P = 0.077, Fig. 6Aa, Ac). Moreover, both rat 
groups showed a delayed and transient increase in resting time during ZT 16-18, 
described previously as a secondary recovery phase after an initial peak of activity in 
the dark (Franken et al., 1991; Brisbare-Roch et al., 2007; Lanté et al., 2011). In the 
Inj Alm trials, two injections of Alm at ZT 18 and ZT 21 were applied to ensure OXR 
block during the entire second half of the dark phase (see Methods). Veh injections 
occurred at equal ZTs in the Inj Veh trial. After Alm injections, rats rested significantly 
more than during the corresponding times in the Bsl Alm trial (mean 5 h resting time, 
ZT 18-23: Inj Alm: 66.5 ± 1.8%; Bsl Alm: 38.8 ± 1.5%, P = 0.0006, Fig. 6Ab, Ad). On 
the contrary, in the Veh group, resting behavior was not different in the Bsl Veh and 
Inj Veh trials (mean 5 h resting time, ZT 18-23: Inj Veh: 33.2 ± 2.9%, Bsl Veh: 39.8 ± 
3.7%, P = 0.28, Fig. 6Ab, Ad), confirming the sedative action induced by Alm but not 
Veh injections. When recording from CA3 cells in slices prepared at ZT 23 from Alm-
injected animals, we found that bath-applied ox-A (100 nM) suppressed NMDA-
currents to 87.2 ± 3.3% of baseline (n = 11, P = 0.002, Fig. 6Ba). Conversely, 
exogenous ox-A (100 nM) did not affect the amplitude of NMDA-currents in the Veh-
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injected group (97.4 ± 3.1%, n = 8, P = 0.53, Fig. 6Bb), in agreement with the results 
from undisturbed animals sacrificed at the same ZT.  
Therefore, by inhibiting the orexinergic system through the injection of Alm, we 
prevented the build-up of endogenous orexin’s suppressant action on NMDARs 
during this waking period, leaving NMDARs available for modulation by exogenous 
orexin. 
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Discussion 
We have identified the NMDARs as a target for orexin at two separate 
hippocampal excitatory synapses. This finding adds a novel facet to the repertoire of 
orexin’s actions: in addition to its widely demonstrated predominant excitatory effects  
(Leonard & Kukkonen, 2014), the peptide is inhibitory for synaptic NMDAR-mediated 
transmission in a brain area central for mnemonic functions. Orexin-mediated 
inhibition is most strongly expressed and direct at MFs, moderate at SCs, and is 
absent at non-MF synapses in the CA3 area, pointing to a synaptic specificity of ox-A 
actions not only amongst pyramidal cell types, but also within subsets of synapses 
established on the dendritic arbour of the same neurone. We further found that 
endogenous orexins regulate NMDAR-responses according to their daily fluctuations, 
perhaps contributing to a diurnal variation of NMDAR function in the hippocampus. 
Therefore, our study has implications for the consequences of waking on 
hippocampal excitatory communication, and, consequently, for diurnal variability in 
memory performance.  
The identification of a hippocampally targetted action of orexin on excitatory 
synapses complements expression studies describing structural and molecular 
substrates for orexinergic signalling in the hippocampus. Orexinergic fibres enter the 
hippocampus via a dorsal ascending pathway (Peyron et al., 1998) and innervate 
both cellular and dendritic strata across hippocampal subfields, including the hilus , s. 
lucidum in CA3 (Morales et al., 2006) and s. radiatum in CA1 (Selbach et al., 2004). 
Using ox-A- and ox-B-specific antibodies, we confirmed a hippocampus-wide 
invasion by orexinergic fibres, in particular in dendritic synapse-rich regions in both 
CA3 and CA1. Moreover, mRNA for OX1Rs locates to the CA1 area, whereas OX2R 
mRNA is predominantly found in the CA3 area (Marcus et al., 2001), consistent with 
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our identification of OX2Rs as mediators of ox-A actions. In addition to pyramidal 
cells (Hervieu et al., 2001; Cluderay et al., 2002), OXRs are also present on hilar and 
s. lucidum interneurones (Hervieu et al., 2001; Ito et al., 2008), possibly representing 
additional, yet unexplored, sites of action for the endogenous peptides within 
hippocampal circuits. 
Aside from several studies suggesting a role of orexins in hippocampus-
dependent memory formation (Jaeger et al., 2002; Aou et al., 2003; Yang et al., 
2013), evidence for direct orexinergic actions on hippocampal circuitry is scarce 
(Wayner et al., 2004; Akbari et al., 2006, 2007). Several studies indicate that 
cholinergic and monoaminergic nuclei, both heavily innervated by orexinergic fibres, 
regulate hippocampal activity in response to orexinergic excitation (Walling et al., 
2004; Doreulee et al., 2009; Stanley & Fadel, 2012). The present study used an 
isolated hippocampal slice preparation from young adult animals and identified a 
suppression of NMDAR-mediated synaptic transmission that developed over minutes 
and recovered only partially, or not at all, even after prolonged wash-out. The effect 
of ox-A could be long-lasting (see Wang et al., 2014), but a poor wash-out of the 
peptide once it had deeply penetrated into the slice and reached the recorded 
neurone could also prevent the return to baseline responses. Additionally, OX1Rs 
bound to ox-A can maintain G-protein-mediated signalling despite being internalised 
(Milasta et al., 2005; Xu et al., 2012). The suppression was largely preserved in the 
presence of a cocktail of neurotransmitters, found in previous reports to cooperate 
with ox-A in modulating hippocampal excitatory synapses (Selbach et al., 2004; 
Doreulee et al., 2009). Also, our experiments were carried out in the continuous 
presence of GABAA and GABAB receptor blockers to exclude an influence of GABA 
release from OXR-expressing interneurones on MF-CA3 circuitry. NMDA-EPSC 
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inhibition was thus mediated, to a major extent, by a direct action of ox-A on 
hippocampal NMDARs. 
The effect of ox-A was observed only on the NMDA- but not on the AMPA-
component of the MF-EPSCs, arguing in favour of a postsynaptically delimited ox-A 
action. Consistent with this finding, LFF, a sensitive measure of presynaptic function 
that reports on cumulative increases in presynaptic residual Ca2+ levels (Salin et al., 
1996), was unaffected in the presence of ox-A. Finally, ox-A suppressed NMDA-
currents elicited through direct NMDA application specifically on dendritic sites where 
MF terminals arrive. Altogether, although a possible expression of OX2Rs at 
presynaptic sites still needs to be definitely excluded, our combined results indicate 
that ox-A-induced suppression of MF-NMDAR-EPSCs is a predominantly 
postsynaptic process. In the in vivo situation, however, the possibility remains that 
orexinergic fibres act presynaptically on MF synapses through dynorphin and 
glutamate, well-described co-transmitters at orexinergic terminals (Chou et al., 2001; 
Schöne et al., 2012), both of which modulate glutamate release from MF terminals 
(Weisskopf et al., 1993; Nicoll & Schmitz, 2005). 
 Inhibitory effects of ox-A were found at MF synapses, but not at non-MF 
synapses. Placing the stimulation electrode in the granule cell layer allowed us to 
record almost pure MF responses in the CA3 pyramidal neurone, as indicated by 
their near-total block by DCG-IV. Whereas MFs form giant terminals at predominantly 
proximal dendritic portions in s. lucidum, non-MF inputs impinge on more distal 
portions of CA3 apical dendrites, in s. radiatum (Claiborne et al., 1986). These 
findings thus suggest that ox-A acts in a dendritically compartmentalised manner, 
modulating NMDARs at the proximally located MF synapses, while sparing those at 
non-MF synapses. Similar spatially delimited effects were observed upon 
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iontophoretic NMDA application to 100 μm-portions of the dendrite: only proximally, 
but not distally positioned NMDA pulses produced NMDA-currents susceptible to ox-
A. The MF-delimited action could be explained by a selective localisation of OX2Rs 
to s. lucidum but not to s. radiatum, a possibility to be further tested with 
immunohistochemistry. Alternatively, molecular characteristics of NMDARs or 
localised signalling cascades could play a role. For example, lamination of 
expression patterns has been described for NMDAR subunits, with GluN2A 
dominating in s. lucidum and GluN2B in s. radiatum (Watanabe et al., 1998). A 
functional compartmentalisation to s. lucidum exists for protein kinase C (PKC)-
mediated stimulatory actions on NMDARs (Kwon & Castillo, 2008a) and for synaptic 
mGluR-mediated activation of a slow cationic conductance (Heuss et al., 1999). 
MF-NMDARs were long considered of minor relevance for normal MF-
mediated synaptic transmission, in part due to their low expression level compared to 
AMPARs (Fritschy et al., 1998; Watanabe et al., 1998), and due to the presence of 
marked NMDAR-independent forms of long-term plasticity (Nicoll & Schmitz, 2005). 
Overcoming this traditional view, several recent studies now indicate that MF-
NMDARs contribute importantly to CA3 pyramidal cell excitability and plasticity 
(Tsukamoto et al., 2003; Kwon & Castillo, 2008a; Rebola et al., 2008; Astori et al., 
2010; Rebola et al., 2011; Hunt et al., 2013). Electron microscopy revealed that CA3 
spines receiving MF boutons express the NMDAR-modulating adenosinergic A2A and 
mGluR group I receptors in close proximity to the synapse (Rebola et al., 2008; Hunt 
et al., 2013). The OX2R-mediated downregulation of NMDARs thus suggests a 
dedicated arrangement of G-protein coupled receptors on CA3 spines to up- or 
downregulate a NMDAR pool with important roles in basal and activity-dependent 
modification of MF function. 
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GluN2A-containing but not GluN2B-containing NMDARs were detected at MF 
synapses (Fritschy et al., 1998; Watanabe et al., 1998) and are therefore the likely 
final targets of OX2R activation. Consistent with a possible removal of GluN2A from 
the synapse are the observed slow-down of the NMDAR-EPSC decay time course in 
the presence of ox-A, the slow time course of ox-A actions, and the poor recovery. In 
the ventral tegmental area, however, OX2Rs up- rather than downregulate GluN2A-
containing NMDARs through a mechanism involving PKC (Borgland et al., 2006). 
Why OX2Rs do not couple to PKC, known to be present at MFs and to be recruited 
during LTP of NMDAR-EPSCs (Kwon & Castillo, 2008a), and upregulate NMDA-
EPSCs, is unclear. Interesting in this context is that mice have two OX2R variants 
that, upon heterodimerisation, produce receptors with novel signalling properties 
(Wang et al., 2014). Therefore, additional signalling pathways, such as OX2R-
mediated activation of extracellular mitogen-activating protein kinases, extracellular 
signal-regulated kinases, coupling to Gi/o-proteins and subsequent receptor 
modification need to be considered (Zhu et al., 2003; Selbach et al., 2010; Guo & 
Feng, 2012; Wang et al., 2014). The considerable number of possible pathways 
involved, together with the comparatively small size of the synaptic response in ox-A 
and the consequent difficulty in reliably assessing time courses, as well as the 
reduced effect of ox-A on iontophoretic currents, leave an assessment of the 
mechanistic bases of ox-A-mediated modulation open for future investigation.  
Surprisingly, ox-A actions were not observed in slices prepared from rats at 
the end of their active period. Instead, several hours of rest were required to observe 
a suppression of NMDAR-EPSCs by the peptide. Furthermore, treating animals with 
the dual antagonist Alm augmented their resting time during the late dark phase and 
partially restored the effect for exogenous ox-A. This supports the idea that 
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endogenous orexin level in hippocampus shows diurnal fluctuations (Yoshida et al., 
2001) and is involved in a time-of-day dependence of ox-A-induced NMDAR 
regulation. The persistence of endogenous orexinergic actions in the slice is not due 
to the continued presence of a high orexinergic tone in the slice, but likely due to 
maintained effects at the OX2R or the NMDAR level. Thus, high orexinergic levels 
during waking could downregulate OX2Rs, rendering slices prepared then 
unresponsive to exogenous ox-A. Additionally, NMDAR function could already be 
downregulated, occluding further ox-A actions. Our work is the first to demonstrate 
that acute slices preserve some of the functional consequences of endogenous 
orexinergic levels present at the moment of brain dissection. However, alternative 
possibilities remain. For example, a circadian fluctuation in the molecular constitution 
of NMDARs (Ishida et al., 1994) could explain diurnal insensitivity to ox-A. 
Furthermore, although unlikely based on our in vitro results, potential secondary 
contributions from afferent modulatory systems regulated by orexin cannot be 
excluded. Thus, the Alm Inj group showed an almost doubled resting time compared 
to the Veh Inj group in the same five hours of the dark phase, likely accompanied by 
an overall decrease in the activity of orexin-driven wake-promoting systems that 
could, in turn, modulate responsiveness to ox-A. Hippocampus-selective 
manipulation of orexinergic activity is needed to distinguish amongst these 
possibilities. 
Time-of-day-dependent modification of properties at excitatory synapses has 
been previously reported for the amplitude of the evoked field potential in rodent DG 
(Barnes et al., 1977), for transcallosal synaptic strength in rat cortex (Vyazovskiy et 
al., 2008), for the constitution of AMPARs at synapses of layer 5 somatosensory 
cortex pyramidal neurones (Lanté et al., 2011) and for the expression of synaptic 
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adhesion molecules (El Helou et al., 2013). The present work is the first to suggest 
that the wake-promoting compound ox-A, accumulating during the active phase, 
could be directly involved in such modulation. Interestingly, diurnal fluctuations of ox-
A in hippocampus drive a rhythmic increase in amyloid-β peptide in hippocampus, a 
pathogenic factor of Alzheimer’s disease (Kang et al., 2009). Together with our 
results, this suggests that prolonged wakefulness and associated elevation of orexin 
deteriorates hippocampal function and imposes a risk for pathology in the long-term. 
This is not only in line with the fact that circadian time of day affects cognitive 
performance (Goel et al., 2013), but also that sleep deprivation negatively affects 
hippocampal synaptic function (Kopp et al., 2006) and can trigger neurodegeneration 
(Cirelli, 2006). In addition, hippocampal neuronal degeneration due to sleep 
deprivation-induced epileptical seizures is amplified by the action of orexins (Ni et al., 
2014). 
To conclude, our study provides mechanistic insights into how the waking 
state modifies synapses, bringing to attention the consequences of elevated orexin 
levels on molecular processes important for hippocampal learning. The wake-
promoting neurochemical environment could eventually limit the susceptibility of 
hippocampal circuits to undergo plastic strengthening. We propose that such insights 
should be considered in further discussions of general concepts on how waking and 
sleeping drive changes in synaptic function (Tononi & Cirelli, 2014). 
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Figures 
Figure 1. Ox-A reduces NMDA-EPSCs at MFs and at SCs 
Aa, Ab, images depicting immunostainings for ox-A or ox-B proteins in areas 
CA3/DG(Aa) and CA1 (Ab). Ox-A and ox-B containing fibres (some indicated with 
filled arrowheads), sparse and of different size, are found throughout CA3, DG and 
CA1. sp, s. pyramidale; sl, s. lucidum; sr, s. radiatum; sg, s. granulosum. Scale bar 
for Aa and Ab: 20 μm. B, top, schematic shows hippocampal slice with positioning of 
recording and stimulation electrodes. Middle, representative NMDA-EPSCs (mean of 
two successive sweeps), recorded from a CA3 pyramidal neurone in a slice prepared 
at ZT 4, are shown for baseline, during maximal ox-A suppression, after wash-out 
and following DCG-IV application to confirm MF origin. Numbers correspond to the 
time points in the graph shown below. Horizontal dashed lines refer to baseline 
holding current and peak of the NMDA-EPSC before ox-A application. Bottom, mean 
NMDA-EPSC amplitudes, expressed as % of baseline, are plotted against time (n = 
10). Horizontal dashed lines indicate mean EPSC levels before and after 10 min of 
ox-A application. C, Time course of Ri and Rs corresponding to B. Vertical lines 
indicate time period of ox-A and DCG-IV application in B and C. D, concentration-
response curve for ox-A-induced inhibition of MF-NMDA-EPSCs, with 1, 10, 50, 100 
and 200 nM tested (n = 2 - 10 recordings from different cells per concentration). Data 
were fitted with a Hill equation, yielding IC50 = 62 ± 17 nM (value indicated by dotted 
lines) and a Hill coefficient nH = 0.6 ± 0.1. E, top, schematic as in B. Middle, 
Representative SC-NMDA-EPSCs recorded from a CA1 pyramidal neurone in a slice 
prepared at ZT 4, are shown for baseline, in ox-A, after wash-out and in D,L-APV. 
Numbers and horizontal dashed lines are as in B. Bottom, graph of time course of ox-
A actions on SC-NMDA-EPSCs (n = 4), in % of baseline. F, Corresponding time 
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course of Ri and Rs, vertical lines as in C. G, top, representative MF-AMPA-EPSCs 
(mean of 2 successive sweeps) in a CA3 pyramidal neurone recorded in a slice 
prepared at ZT 4, during baseline, in ox-A and after DCG-IV application. Horizontal 
dashed lines are used as in B and E. Bottom, bar graph representing mean AMPA-
EPSC amplitudes expressed as % of baseline (n = 3). Ox-A effect was measured 10 
min after application onset, DCG-IV blocked the response. Data are presented as 
mean ± SEM. 
 
Figure 2. Ox-A does not modify NMDA-EPSCs at non-MF to CA3 synapses 
A, top, Representative NMDA-EPSCs (mean of 2 successive sweeps), elicited 
through hilum/s. lucidum stimulation and recorded in a slice prepared at ZT 4, are 
shown for baseline, during maximal ox-A action, after wash-out and after DCG-IV 
application. Numbers correspond to the time points in the graph shown below. 
Horizontal dashed lines refer to baseline holding current and peak of NMDA-EPSC 
before ox-A application. Bottom, time course of mean NMDA-EPSC amplitudes in %, 
with horizontal lines indicating 100% and suppression of ox-A, measured 10 min after 
application onset (n = 4). DCG-IV induced a partial block of NMDA-EPSCs, indicating 
that a mixture of MFs and non-MFs was recruited. Inset, schematic of recording 
configuration, indicating in particular the positioning of the stimulation pipette in the 
hilus/s. lucidum. B, similar experiment as in A, except that iontophoretic (ionto) 
application of NMDA was used to elicit NMDA-currents at distal dendritic sites (see 
inset). The pipette was positioned ~250 µm from the cell body to activate NMDARs 
preferentially at non-MF synapses. Corresponding representative traces and time 
course are shown (n = 8). Horizontal lines are used as in A. Data are presented as 
mean ± SEM. C, Same experiment as B, but for iontophoretic NMDA application on 
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proximal dendritic sites. In B and C, D,L-APV fully blocked the iontophoretic current 
responses. D, Least-squares linear regression analysis of DCG-IV sensitivity and ox-
A sensitivity for 14 recordings with low to intermediate suppression by DCG-IV (to 15-
60% of control amplitude), which includes the four cells presented in panel A. The 
slope of the regression curve is 1.02, with R2 = 0.366 and P = 0.0219. 
 
Figure 3. Ox-A leaves low-frequency facilitation of MF synapses unaltered 
A, mean time course of LFF of MF-NMDA-EPSCs (n = 5), evoked by increasing the 
stimulation frequency from 0.033 Hz to 1 Hz (indicated on top of the graph). Note 
that, although EPSCs show a gradual run-up during the initial 0.033 Hz stimulation, a 
strong, several-fold increase in EPSC amplitude occurred during the 20 pulses at 1 
Hz that recovered after 0.033 Hz stimulation was resumed. After ox-A (100 nM) 
application, NMDA-EPSC amplitude decreased, but LFF persisted. EPSC amplitudes 
before and in ox-A were normalised to their respective baseline values at 0.033 Hz 
and set to 100%. B, raw traces (mean of 2 sweeps) corresponding to an experiment 
shown in A. Note that baseline NMDA-EPSCs were reduced in ox-A, but LFF was 
fully developed. Numbers correspond to the time points in the graph shown in A. 
Horizontal lines refer to baseline holding current and peak NMDA-EPSC at 0.033 Hz. 
C, bar graphs summarising mean relative values of LFF in control (black bars) and in 
ox-A (grey bars) (n = 5). The amplitude of LFF was obtained by dividing the mean 
EPSC amplitudes during the last 5 sweeps in the 1 Hz train by the mean of the 5 
baseline sweeps. Relative values of LFF were not altered in ox-A. Steady-state 
EPSC amplitudes at 0.033 Hz after the 1 Hz train are also indicated. Data are 
presented as mean ± SEM. 
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Figure 4. Ox-A actions on MF-NMDARs are mediated by OX2Rs 
A, B, pharmacological dissection of ox-A actions through continuous bath application 
of the OX1R antagonist, SB334867 (A), or the OX2R antagonist, JNJ10397049 (B). 
Time courses for both pharmacological tests, performed on iontophoretic NMDA-
currents in slices prepared at ZT 4, indicate that ox-A-induced suppression of NMDA-
currents was maintained in SB334867 (1 μM, n = 7, A), but abolished in 
JNJ10397049 (1 μM, n = 8, B). C, Ox-A actions were assessed in the presence of a 
cocktail of scopolamine (non-selective muscarinic antagonist, 10 μM), prazosin and 
D,L-propranolol (α- and β-adrenergic antagonists, respectively, 1 μM each) (n = 5). 
Ox-A inhibition developed fully, but more slowly than in the absence of these 
antagonists. D, Representative NMDA-currents for experiments in A, B and C. Lower 
case letters correspond to the experiments in A, B and C, respectively, and numbers 
to the points in the respective time courses. Horizontal lines indicate baseline holding 
and peak NMDA-current values before ox-A application. Data are presented as mean 
± SEM. 
 
Figure 5. Exogenous ox-A effects are dependent on the time-of-day of slice 
preparation 
A, representative NMDA-currents evoked iontophoretically on proximal CA3 
dendrites, in slices prepared during different ZTs, as indicated to the left of the traces. 
Traces in the presence of ox-A and D,L-APV are also shown. Time points chosen for 
slice preparation correspond to the peak of ox-A cerebral spinal fluid levels (ZT 23), 
and to the minimum (ZT 4, ZT 8) (Zhang et al., 2004). Note that ox-A inhibitory 
effects are minor at ZT 23, but fully developed at ZT 4 and ZT 8. B, time course of ox-
A actions in slices prepared at these three different times of day (ZT 23, n = 12; ZT 4, 
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n = 12; ZT 8, n = 4), with mean NMDA-EPSC amplitudes, expressed as % of 
baseline. At ZT 4, 9 datapoints presented in Fig. 2C were included. 100% is indicated 
by the horizontal line. C, bar graphs representing mean ox-A inhibition at these 
different ZT values. Asterisks represent significance relative to baseline NMDA-
currents. *, P < 0.05; **, P < 0.01. D, Left, Time course of NMDA-currents in the 
continuous presence of JNJ10397049 (1 μM). NMDA-currents remained unaltered 
over >25 min (n = 6), arguing against a tonic suppression by endogenous orexins 
present in the slice. Responses were fully blocked by D,L-APV. Dotted line indicates 
100%. Right, representative traces corresponding to the graph on the left. Dotted 
lines denote baseline holding and peak NMDA-current amplitude before drug wash-
in. Data are presented as mean ± SEM.  
 
Figure 6. Almorexant administration restores the actions of exogenous ox-A on 
NMDARs 
Aa, distribution of resting time of the Veh and Alm groups of rats across the LD cycle, 
during the Bsl Alm (squares) and Bsl Veh (circles) trials. Resting time was quantified 
as % timeh-1 below a visually set threshold of locomotor activity (see Methods). Rats 
rested more during the light phase (ZT 1-12, unshaded portion of the graph) 
compared to the dark phase (ZT 13-24, shaded) (Alm group, n = 8; Veh group, n = 
6). Ab, mean resting time of the Alm and Veh groups over ZT 18-23 of the Inj trials, 
during which two I.P. injections of Alm or Veh were administered at ZT 18 and ZT 21 
(arrows). The Alm group rested more than in the corresponding 5 h period in the 
preceding Bsl Alm trial, while resting time of the Veh group was unaltered. Ac and 
Ad, summarising bar graphs of mean resting times for the 12 h light and 12 h dark 
periods (Ac) and for the 5 h dark periods after Alm or Veh injection, respectively (Ad). 
37 
 
In the Veh group, all but one animal showed a decreased resting time in the dark 
compared to the light phase of the Bsl trial, rendering P non-significant (0.077) for the 
right column pair in Ac. Exclusion of this animal would decrease P to 0.008. The 
animal was kept for further analysis as it showed regular behaviour in the subsequent 
Inj trial. Ba, Bb, ox-A actions on iontophoretic NMDA-currents in slices prepared at 
ZT 23 from the Alm (Ba) and Veh (Bb) groups. The actions of bath-applied ox-A were 
recovered in the Alm group (n = 11), but not in the Veh group (n = 8). Horizontal lines 
represent 100% and mean ox-A-induced suppression. Data are presented as mean ± 
SEM. n.s., P > 0.05; *, P < 0.05; ***, P < 0.001.  
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